DurAVR™ has been implanted in 50 patients (44 with severe aortic stenosis and six valve-in-valve cases
to rectify prosthetic valve failure). Clinical results to date demonstrate this new class of biomimetic valve
outperforms the market leader, returning patients to a near normal haemodynamic (blood flow) state.
Ann: Capital Raise, page-5
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.00 |
Change
0.100(0.53%) |
Mkt cap ! $365.2M | |||
| Open | High | Low | Value | Volume |
| $18.88 | $19.00 | $18.59 | $81.83K | 4.377K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 520 | $18.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.00 | 200 | 1 |
View Market Depth
| Last trade - 15.49pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.00 |
Change
0.100 ( 0.65 %) |
||||
| Open | High | Low | Volume | ||
| $19.00 | $19.00 | $19.00 | 1 | ||
| Last updated 15.53pm 07/06/2024 ? | |||||
| AVR (ASX) Chart |